肿瘤相关癫痫是诊断为弥漫性神经胶质瘤的患者最常见的症状。最近的证据表明突触活动需要驱动神经胶质瘤的增殖和侵袭。关于使用抗癫痫药物 (AED) 与化疗联合进行抗肿瘤治疗的 1、2 和 3 类证据有限。此外，还没有哪个中央机制成为最有针对性的。 AED 治疗的最佳时机仍不清楚。针对异常神经元活动是神经胶质瘤治疗的一个有前途的途径。临床生物标志物可能有助于识别最有可能从 AED 中受益的患者。需要高质量的证据来指导治疗决策。版权所有 © 2024。由 Elsevier Inc. 出版。

Tumor-associated epilepsy is the most common presenting symptom in patients diagnosed with diffuse gliomas. Recent evidence illustrates the requirement of synaptic activity to drive glioma proliferation and invasion. Class 1, 2, and 3 evidence is limited regarding the use of antiepileptic drugs (AEDs) as antitumor therapy in combination with chemotherapy. Furthermore, no central mechanism has emerged as the most targetable. The optimal timing of AED regimen remains unknown. Targeting aberrant neuronal activity is a promising avenue for glioma treatment. Clinical biomarkers may aid in identifying patients most likely to benefit from AEDs. Quality evidence is needed to guide treatment decisions.Copyright © 2024. Published by Elsevier Inc.